Delaware | 000-21429 | 04-3221586 | ||
(State or other jurisdiction | (Commission File Number) | (I.R.S. Employer | ||
of incorporation) | Identification No.) |
19 Presidential Way | ||
Woburn, MA | ||
(Address of principal executive offices) |
01801 | ||
(Zip code) |
(781) 994-0300 | ||
(Registrant’s telephone number, including area code) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Section 8 — Other Events
Item 8.01 Other Events.
On May 30, 2014, ArQule, Inc. (the “Registrant”) announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30 to June 3 in Chicago, Illinois.
The presentations will feature tivantinib in clinical trials across multiple diseases and therapeutic combinations. Data will relate to the safety and combinability of tivantinib with approved anti-cancer agents, supporting the ongoing development of this compound.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit | 99.1 Text of press release dated May 30, 2014 announcing ASCO presentations |
2 |
ARQULE, INC. | ||
(Registrant) | ||
/s/ Peter S. Lawrence | ||
Peter S. Lawrence | ||
President and Chief Operating Officer |
3